



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

28 November 2012

Extra Ordinary General Meeting To Set Future Direction

The Company (ASX: BXN) advised on 29 September 2012, that it has signed a heads of agreement with Vaxine Pty Ltd (Vaxine), a biotechnology company based in Adelaide, to develop a study to continue investigation into the effectiveness of HI 164 on a selected group of patients with Chronic Obstructive Pulmonary Disease (COPD). The Company has reached in-principle agreement with Vaxine to the study protocol and process.

The proposed funding for this study involved the issue of equity to Vaxine, subject to shareholders' approval. The Company advises that Resolution 4 will be withdrawn from the agenda of the upcoming AGM.

A notice of meeting for an Extraordinary Shareholders Meeting will be convened shortly to determine the future direction of the Company. Shareholders will have the opportunity to participate in the decision as to whether the proposed study with the HI 164 asset to continue, or, to cease development of HI 164 and pursue alternative opportunities. Details of the proposed transaction with Vaxine will accompany the notice of meeting.

Shareholders will also be asked to approve a capital raising of up to \$2.0m to provide working capital to enable the Company to implement the direction as approved by them pursuant to the notice of meeting.

The notice of meeting is scheduled for despatch later this week with the date of the EGM to be held early in January 2013.

For Further information please contact:

David Radford

Chief Executive Officer

Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes

CityPR

(02) 9267 4511



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business commercialising a new therapy for patients with Chronic Obstructive Pulmonary Disease (COPD). Its lead product HI-164 is based on the proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164 works by controlling bacterial infections of airways damaged by toxins. HI-164 recently completed a Phase IIb clinical trial for COPD where it was shown to be effective in a subset of the patient cohort under the age of 65. The company is planning a new study to further determine HI-164's efficacy in patients under the age of 65.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets worldwide. An analysis by the Australian Lung Foundation in 2008 indicated the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer. COPD is Australia's second leading cause of avoidable hospital admissions.